Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects~ 1% of the
Caucasian population. Over the last decades, the availability of biological drugs targeting …

Genetic biomarkers could potentially lower the risk of treatment failure in chronic
inflammatory diseases (CID) like psoriasis, psoriatic arthritis (PsA), rheumatoid arthritis (RA) …

We evaluated the influence of clinical, biochemical, and genetic factors on response in 142
patients diagnosed with rheumatoid arthritis, of whom 87 patients were treated with …

Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal
antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of …

The aim of this study was to investigate the influence of clinical and genetic factors on
response to tocilizumab (TCZ) response, remission, low disease activity (LDA) and DAS28 …

In the present study, we aimed to investigate the influence of clinical parameters and single-
nucleotide polymorphisms of interleukin-6 receptor (rs12083537, rs2228145, rs4329505 …

Biological disease-modifying anti-rheumatic drugs (bDMARDs) have changed care of
patients with rheumatoid arthritis (RA). However, bDMARDs are costly, can lead to serious …

The 'totality-of-the-evidence'biosimilarity concept requires that sufficient structural, functional,
nonclinical, and clinical data are acquired in a stepwise manner, to demonstrate that no …

Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis
(RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide …

Background Sarilumab, an IL-6 receptor antagonist, is a first-line biologic disease-modifying
anti-rheumatic drug for rheumatoid arthritis. The identification of genetic biomarkers as …